Zacks: Brokerages Expect Dynavax Technologies Co. (DVAX) Will Announce Earnings of -$0.58 Per Share

Equities analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Dynavax Technologies’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.60). Dynavax Technologies reported earnings of ($0.38) per share in the same quarter last year, which would indicate a negative year over year growth rate of 52.6%. The company is expected to report its next earnings results after the market closes on Monday, November 5th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.33). For the next year, analysts forecast that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Dynavax Technologies.

A number of analysts have recently weighed in on the company. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Cowen reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, October 22nd. Royal Bank of Canada increased their price objective on Dynavax Technologies to $26.00 and gave the company an “outperform” rating in a research note on Monday, October 22nd. Cantor Fitzgerald upped their target price on Dynavax Technologies to $32.00 and gave the company an “overweight” rating in a report on Monday, October 22nd. Finally, BidaskClub upgraded Dynavax Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Dynavax Technologies currently has an average rating of “Hold” and an average target price of $28.25.

Shares of NASDAQ:DVAX traded down $0.03 during trading on Wednesday, reaching $11.37. 6,069 shares of the company traded hands, compared to its average volume of 1,715,204. The firm has a market cap of $713.82 million, a PE ratio of -6.51 and a beta of 0.61. Dynavax Technologies has a 52-week low of $9.63 and a 52-week high of $23.85. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87.

Institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can raised its holdings in shares of Dynavax Technologies by 365.4% during the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,943 shares in the last quarter. Chicago Capital LLC raised its holdings in Dynavax Technologies by 48.3% in the second quarter. Chicago Capital LLC now owns 1,294,104 shares of the biopharmaceutical company’s stock worth $19,735,000 after purchasing an additional 421,446 shares in the last quarter. Creative Planning raised its holdings in Dynavax Technologies by 2.6% in the second quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock worth $3,585,000 after purchasing an additional 5,857 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in Dynavax Technologies in the first quarter worth $200,000. Finally, Tiverton Asset Management LLC bought a new position in Dynavax Technologies in the second quarter worth $184,000. Institutional investors own 81.48% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Read More: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply